首页> 外文期刊>Journal of neurosurgery. >Multicenter study of the feasibility and safety of using the memotherm carotid arterial stent for extracranial carotid artery stenosis.
【24h】

Multicenter study of the feasibility and safety of using the memotherm carotid arterial stent for extracranial carotid artery stenosis.

机译:关于使用颈外动脉支架治疗颅外颈动脉狭窄的可行性和安全性的多中心研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECT: Carotid artery (CA) angioplasty with stent placement has been proposed as an alternative technique for revascularization in cases of CA stenosis. In this report the authors review the results of a multicenter Phase I study in which they evaluated the safety and feasibility of using a new self-expanding nitinol stent, the Bard Memotherm, to treat CA stenosis. METHODS: Enrollment was limited to patients in whom there was either 50% or greater symptomatic or 70% or greater asymptomatic stenosis of the internal CA. The primary endpoint was a technically successful implantation procedure (delivery of the stent to the target site and retrieval of the delivery device), resulting in less than 30% residual stenosis demonstrated on immediate postprocedure (control) angiograms, and no incidence of mortality, ipsilateral stroke, Q-wave myocardial infarction, or other major cardiovascular events immediately after or within 30 days following the procedure. Stent placement was attempted for 73 lesions in 71 patients (mean age 71.3 +/- 8.5 years), 43 (61%) of whom were men. The mean degree of stenosis was 82.6 +/- 9%. The stenosis was symptomatic in 27 (37%) and asymptomatic in 46 (63%) of 73 lesions. In four procedures the stent could not be delivered or released. The mean residual stenosis observed on angiograms was 3.8 +/- 6.9% in the 69 lesions treated with the Bard Memotherm stent; residual stenosis was greater than 30% in one of the 69 procedures. The primary endpoint was achieved in 65 (89%) of the 73 procedures. One patient experienced a major ischemic stroke and another patient died of intracerebral hemorrhage. The overall 1-month stroke rate was 2.7% for 73 attempted procedures. One patient died of pneumonia and acute respiratory distress syndrome, which occurred 3 weeks after the stent procedure and was unrelated to the procedure. CONCLUSIONS: The Memotherm stent can be used to treat patients with CA stenosis and is associated with a low peri-procedure complication rate. Long-term follow-up studies are underway to determine the impact of stent placement on the risk of ipsilateral ischemic events.
机译:目的:已提出在支架狭窄的情况下,采用颈动脉血管成形术和支架置入术作为血运重建的替代技术。在本报告中,作者回顾了一项多中心I期研究的结果,在该研究中,他们评估了使用新型自膨胀镍钛诺支架Bard Memotherm来治疗CA狭窄的安全性和可行性。方法:入组仅限于内部CA有50%或以上症状或70%或以上无症状狭窄的患者。主要终点是技术上成功的植入程序(将支架输送到目标部位并取出输送装置),从而在术后立即(对照)血管造影照片上证实残留狭窄少于30%,且无同侧死亡率手术后或手术后30天内立即发生中风,Q波心肌梗塞或其他重大心血管事件。尝试对71例患者(平均年龄71.3 +/- 8.5岁)中的73个病变进行支架置入,其中43例(61%)为男性。平均狭窄度为82.6 +/- 9%。在73个病变中,有症状的狭窄为27个(37%),无症状的为46个(63%)。在四种手术中,支架不能被输送或释放。在Bard Memotherm支架治疗的69个病变中,在血管造影照片上观察到的平均残余狭窄为3.8 +/- 6.9%。在69例手术之一中,残余狭窄大于30%。 73例手术中有65例(89%)达到了主要终点。一名患者经历了严重的缺血性中风,另一名患者死于脑出血。 73次尝试手术的总1个月中风率为2.7%。 1例患者死于肺炎和急性呼吸窘迫综合征,这发生在支架手术后3周,与该手术无关。结论:Memotherm支架可用于治疗CA狭窄患者,并具有较低的围手术期并发症发生率。正在进行长期随访研究,以确定支架放置对同侧缺血事件风险的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号